A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
Eli Lilly and Company
Bristol-Myers Squibb
Cancer Research UK
Turning Point Therapeutics, Inc.
Novartis
Frontier Medicines Corporation
Filamon LTD
PMV Pharmaceuticals, Inc
Mayo Clinic
M.D. Anderson Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
A2 Biotherapeutics Inc.
Essen Biotech
Revolution Medicines, Inc.
Auricula Biosciences Inc.
Grey Wolf Therapeutics
3H Pharmaceuticals Co., Ltd.
M.D. Anderson Cancer Center
Second Life Therapeutics
Eli Lilly and Company
Inhibrx Biosciences, Inc
VM Oncology, LLC
Takeda
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
NantCell, Inc.
Revolution Medicines, Inc.
Hadassah Medical Organization
LigaChem Biosciences, Inc.
Shanghai Escugen Biotechnology Co., Ltd
A2 Biotherapeutics Inc.
Incyte Corporation
Marengo Therapeutics, Inc.
Cancer Research UK
Hoffmann-La Roche
Gustave Roussy, Cancer Campus, Grand Paris
Intensity Therapeutics, Inc.
Evopoint Biosciences Inc.
NextCure, Inc.
Coherent Biopharma (Hefei) Co., Ltd.
Chongqing Precision Biotech Co., Ltd
NantCell, Inc.
Second Affiliated Hospital of Guangzhou Medical University
NextCure, Inc.
Mural Oncology, Inc
NKGen Biotech, Inc.
University of Saskatchewan
Fusion Pharmaceuticals Inc.
Klus Pharma Inc.